1/ Increasing vaccine protection against #COVID. A/Prof @SAlonsoGroup@NUSingapore & A/Prof @LahoudMirei@MonashBDI have discovered a technique for prolonging immune response to #SARSCoV2 virus in pre-clinical models using an antibody construct. More: https://t.co/obST1WhQut
Delighted to celebrate our latest publication with A/Prof Sylvie Alonso @SAlonsoGroup on dendritic cell-targeting of SARS-CoV-2 antigens for durable and protective immunity.
A fantastic collaboration between @MonashBDI and @NUSingapore.
https://t.co/zlzVHEndje
📢Don't miss our BDI seminar this Fri 17 May, 12-1pm!
𝗦𝗽𝗲𝗮𝗸𝗲𝗿: A/Prof Sylvie Alonso @SAlonsoGroup@nusingapore
𝗧𝗼𝗽𝗶𝗰: A versatile & powerful dendritic cell-targeting platform to deliver vaccine antigen candidates against infectious diseases
https://t.co/aEn6I6trbH
Featuring our new publication on @MolTherapy deeply characterizing a cDC1 targeting vaxx strategy we have focused on for years, this time in SARS-CoV-2 context. Overall, our findings present its promise as a next gen pandemic response vaxx strategy Congrats to @_immunogeNIC agn!
Proudly sharing that the 1st phase of my PhD work is officially published! Here, we characterized the immune response elicited by a Clec9A-cDC1 targeting SARS-CoV-2 vaccine. Thankful for @NUSMedAlonsoS guidance and all coauthors' contributions! See below our summarized findings.
Had an engaging week at the #IVBDC2023: Shared our work on mosquito reproduction & population genomics; Was inspired by cool science & emerging technology in vector control; Had fun catching up with ex-students! Big 🙏🏾 to @SAlonsoGroup & @NUS_DBS
Featuring the boss @NUSMedAlonsoS presenting a translational and exciting story about the lab's cDC1 targeting vaccine research at the annual SgSI symposium. 🎉🎉🎉